Durvalumab improves prognosis of stage III non-small-cell lung cancer after definitive chemoradiotherapy

Hecht M, Gaipl U, Fietkau R (2018)

Publication Type: Journal article

Publication year: 2018

Journal

Strahlentherapie und Onkologie Urban & Vogel

Book Volume: 194

Pages Range: 269-271

Journal Issue: 3

DOI: 10.1007/s00066-017-1253-3

Authors with CRIS profile

Markus Hecht Department of Radiation Oncology Udo Gaipl Department of Radiation Oncology Rainer Fietkau Lehrstuhl für Strahlentherapie

How to cite

APA:

Hecht, M., Gaipl, U., & Fietkau, R. (2018). Durvalumab improves prognosis of stage III non-small-cell lung cancer after definitive chemoradiotherapy. Strahlentherapie und Onkologie, 194(3), 269-271. https://dx.doi.org/10.1007/s00066-017-1253-3

MLA:

Hecht, Markus, Udo Gaipl, and Rainer Fietkau. "Durvalumab improves prognosis of stage III non-small-cell lung cancer after definitive chemoradiotherapy." Strahlentherapie und Onkologie 194.3 (2018): 269-271.

BibTeX: Download